Article Text

Download PDFPDF

P2.017 Clinical Evaluation of the PelvoCheck® CT/NG For the Detection of Chlamydia Trachomatis and Neisseria Gonorrhoeae
  1. A Kilic1,
  2. R Kofler2,
  3. K Hänel1,
  4. T Meyer3
  1. 1Greiner Bio-One GmbH, Frickenhausen, Germany
  2. 2Lambda GmbH, Rainbach, Austria
  3. 3Institut für Medizinische Mikrobiologie, Virologie und Hygiene, Universitätsklinikum Hamburg-Eppendorf (UKE), Germany


Background In the present study the performance of the PelvoCheck® CT/NG, a microarray-based nucleic acid amplification assay for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), was evaluated in single and pooled urine specimen of young women.

Methods A total of 1649 female urine specimens were collected and examined for urogenital chlamydia infections. Because of a low prevalence (2.12%), 50 CT-negative urine specimens were enriched with CT reference material mimicking the natural chlamydial distribution in female urine. The results were compared to those of the Roche COBAS® TaqMan® CT assay as the first and the Abbott RealTime CT/NG assay as the second reference method.

Similarly, NG pre-screened female urine specimens (60 NG-positive and 60 NG-negative specimens) were analysed with the PelvoCheck® CT/NG test and compared to a validated in-house Q-PCR method and the Abbott RealTime CT/NG assay.

Furthermore, the PelvoCheck® CT/NG assay was tested for pooled urine specimens (52 CT-negative and 55 CT-positive specimens). Each pool consisted of either five individual CT-negative specimens or four CT-negative and one CT-positive individual specimens.

Results For the detection of CT the overall positive agreement (sensitivity) and overall negative agreement (specificity) of the PelvoCheck® CT/NG were 98.8% and 100%, for the detection of NG 98.3% and 98.2%, respectively.

The comparison of data obtained with the PelvoCheck® CT/NG for pooled urine specimens resulted in a positive agreement of 90.9% and a negative agreement of 100%. Four CT-positive pooled specimens with final CT-concentrations of 0.05 – 0.13 IFU/ml were not detected.

Conclusion In summary, we show that the PelvoCheck® CT/NG assay is a highly sensitive and highly specific method for the detection of CT and NG. To our knowledge, this is the first commercial CT/NG test system validated for the analysis of pooled urine specimens.

  • Chlamydia trachomatis
  • clinical evaluation
  • Neisseria gonorrhoeae

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.